Publication date: Jun 25, 2025
Emergency laparotomy (EL) is associated with high post-operative morbidity. This study aims to evaluate the sustainability of our peri-operative pathway for EL (Emergency Laparotomy Pathway (ELAP)) during the COVID-19 pandemic. This is a single-center retrospective study on patients who underwent EL following ELAP implementation from Jan 2019-Dec 2022. Exclusion criteria were EL for trauma or vascular surgery. The cohort was divided based on the COVID-19 pandemic (COVID was defined from 7 Feb 2020-25 Apr 2022). Cumulative sum (CUSUM) analysis was used to assess the chronologic performance of ELAP. Our primary outcomes were efficiency outcomes (time to surgery, presence of senior surgeon/anaesthetist in theatre and post-operative geriatric review). Our secondary outcomes were post-operative complications, major morbidity, and 30-day mortality. There were 564 patients (30. 5% pre-COVID, 52. 1% COVID, 17. 4% post-COVID). The median age was 66. 0 years, and 57. 6% had ASA score ≥ 3. The commonest indication for EL was intestinal obstruction (56. 9%). Overall major morbidity was 14. 0%, and 30-day mortality was 2. 8%. CUSUM analysis showed two phases-exploration phase (Case 1-158) and proficiency phase (Case 159-564); an inflection point was noted following the exploration phase, which showed a more sustained performance in achieving post-operative geriatric review and absence of post-operative complications or major morbidity. There was no observed relationship between COVID-19 and the performance of ELAP in both efficiency and clinical outcomes. The good performance of ELAP was sustained at 4 years following its initial implementation despite the COVID-19 pandemic, which resulted in major disruptions to healthcare delivery.
| Concepts | Keywords |
|---|---|
| 4years | emergency surgery |
| Anaesthetist | frailty |
| Covid | laparotomy |
| High | peri‐operative care |
| quality improvement |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Spinosad |
| disease | MESH | Emergency |
| disease | MESH | COVID-19 Pandemic |
| disease | MESH | morbidity |
| disease | MESH | complications |
| drug | DRUGBANK | Acetylsalicylic acid |
| disease | MESH | intestinal obstruction |
| disease | MESH | frailty |
| disease | IDO | quality |